GSK1325756
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract Background Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a…
From the GlaxoSmithKline trial of danirixin: “The inflammation associated with chronic obstructive pulmonary disease (COPD) is…
Background: Danirixin (DNX) is a competitive, reversible CXCR2 chemokine receptor antagonist. CXCR2 antagonists inhibit…
BackgroundExcessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases. The…
Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of…
Characterization of the biliary disposition of GSK1325756, using a non‐invasive bile sampling technique and spectrometric…